Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: Implications for cancer immunotherapy

Clinical Cancer Research

Volumn 14, Issue 20, 2008, Pages 6574-6579

  Kondo, Eisei ^a,b   Maecker, Britta ^d   Weihrauch, Martin R ^a,b   Wickenhauser, Claudia ^c   Zeng, Wanyong ^e   Nadler, Lee M ^e,f,g   Schultze, Joachim L ^h   Von Bergwelt Baildon, Michael S ^a,b,c  

^a 1St Department of Internal Medicine   (Germany)

^b Max Eder Nachwuchsgruppe der Deutschen Krebshilfe   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CD40 ANTIGEN; CYCLIN D1; EPITOPE; GAMMA INTERFERON; HLA A ANTIGEN; HLA A2 ANTIGEN; CCND1 PROTEIN, HUMAN; HLA A*0201 ANTIGEN; HLA-A*0201 ANTIGEN; PEPTIDE FRAGMENT; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE ACTIVATION; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL EXPANSION; CLASSIFICATION ALGORITHM; COLON CANCER; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; B LYMPHOCYTE; COLON TUMOR; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PATHOLOGY;

ANTIGEN-PRESENTING CELLS; ANTIGENS, CD40; B-LYMPHOCYTES; COLONIC NEOPLASMS; CYCLIN D1; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; LYMPHOMA, MANTLE-CELL; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 58149199123     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0825     Document Type: Article

References (40)

1. Sadovnikova E, Jopling LA, Soo KS, Stauss HJ. Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. Eur J Immunol 1998;28:193-200.
2. Hunter T, Pines J. Cyclins and cancer. Cell 1991;66:1071-4.
3. Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg SA. Cloning genes encoding MHC class Il-restricted antigens: mutated CDC27 as a tumor antigen. Science 1999;284:1351-4.
4. Wolfel T, Hauer M, Schneider J, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281-4.
5. Kao H, Marto JA, Hoffmann TK, et al. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med 2001;194:1313-24.
6. Dahl AM, Beverley PC, Stauss HJ. A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein. J Immunol 1996;157:239-46.
7. Muller H, Lukas J, Schneider A, et al. Cyclin D1 expression is regulated by the retinoblastoma protein. Proc Natl Acad Sci U S A 1994;91:2945-9.
8. Ratschiller D, Heighway J, Gugger M, et al. Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival.J Clin Oncol2003;21:2085-93.
9. Arber N, Hibshoosh H, Moss SF, et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 1996;110:669-74.
10. Arber N, Gammon MD, Hibshoosh H, et al. Overex-pression of cyclin D1 occurs in both squamous carcinomas and adenocarcinomas of the esophagus and in adenocarcinomas of the stomach. Hum Pathol 1999;30:1087-92.
11. Weinschenk T, Gouttefangeas C, Schirle M, et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res 2002;62:5818-27.
12. Dengjel J, Decker P, Schoor O, et al. Identification of a naturally processed cyclin D1 T-helper epitope by a novel combination of HLA class II targeting and differential mass spectrometry. Eur J Immunol 2004;34:3644-51.
13. Gao L, Yang TH, Tourdot S, Sadovnikova E, Hasserjian R, Stauss HJ. Allo-major histocompatibility complex-restricted cytotoxic T lymphocytes engraft in bone marrow transplant recipients without causing graft-versus-host disease. Blood1999;94:2999-3006.
14. Schultze JL, Michalak S, Seamon MJ, et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 1997;100:2757-65.
15. von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 2002;99:3319-25.
16. Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 2003;63:2836-43.
17. Kondo E,Topp MS, Kiem HP, et al. Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. J Immunol 2002;169:2164-71.
18. von Bergwelt-Baildon M, Shimabukuro-Vornhagen A, Popov A, et al. CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants. Blood 2006;107:2786-9.
19. Maecker B, Sherr DH,Vonderheide RH, et al. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood 2003;102:3287-94.
20. Vonderheide RH, Schultze JL, Anderson KS, et al. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res 2001;61:8366-70.
21. Hirano N, Butler MO, Von Bergwelt-Baildon MS, et al. Autoantibodies frequently detected in patients with aplastic anemia. Blood 2003;102:4567-75.
22. Maecker B, von Bergwelt-Baildon MS, Sherr DH, Nadler LM, Schultze JL. Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1. Int J Cancer 2005;115:333-6.
23. Schmollinger JC, Vonderheide RH, Hoar KM, et al. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci U S A 2003;100:3398-403.
24. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994;152:163-75.
25. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999;50:213-9.
26. Guan P, Doytchinova IA, Zygouri C, Flower DR. MHCPred: a server for quantitative prediction of peptide-MHC binding. Nucleic Acids Res 2003;31:3621-4.
27. Peters B,Tong W, Sidney J, Sette A,Weng Z. Examining the independent binding assumption for binding of peptide epitopes to MHC-I molecules. Bioinformatics 2003;19:1765-72.
28. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. Thetelomerase catalytic subunitis a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity1999;10:673-9.
29. Bohlen H, Manzke O, Engert A, et al. Differentiation of cytotoxicity using target cells labelled with europium and samarium by electroporation. J Immunol Methods 1994;173:55-62.
30. Cloosen S, Arnold J, Thio M, Bos GM, Kyewski B, Germeraad WT. Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: implications for self-tolerance and tumor therapy. Cancer Res 2007;67:3919-26.
31. Gotter J, Brors B, Hergenhahn M, Kyewski B. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J Exp Med 2004;199:155-66.
32. Shi FD, Zhang JY, Liu D, et al. Preferential humoral immune response in prostate cancer to cellular pro-teins p90 and p62 in a panel of tumor-associated antigens. Prostate 2005;63:252-8.
33. + regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531-62.
34. Taguchi O, Takahashi T. Administration of anti-interleukin-2 receptor α antibody in vivo induces localized autoimmune disease. Eur J Immunol 1996;26:1608-12.
35. Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001;27:20-1.
36. Sprent J. Proving negative selection in the thymus. J Immunol 2005;174:3841-2.
37. Covini G, Chan EK, Nishioka M, Morshed SA, Reed SI, Tan EM. Immune response to cyclin B1 in hepatocellular carcinoma. Hepatology1997;25:75-80.
38. Koziol JA, Zhang JY, Casiano CA, et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 2003;9:5120-6.
39. Suzuki H, Graziano DF, McKolanis J, Finn OJ. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res 2005;11:1521-6.
40. Egloff AM,Vella LA, Finn OJ. Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Res 2006;66:6-9.